United States Cystinuria Treatment Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Viatris Inc., AdvaCare Pharma, Camber Pharmaceuticals, Inc., Bausch Health Companies Inc and Panacea Biotec.

Global cystinuria treatment market reached USD 110.7 million in 2022 and is expected to reach USD 153.8 million by 2030 growing with a CAGR of 4.3% during the forecast period 2023-2030.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/cystinuria-treatment-market?sg

Industry Latest News 2025:

✅ (18 Mar 2025) Cycle Pharmaceuticals / Torrent Pharma launched VENXXIVATM (tiopronin) delayed-release tablets for the treatment of cystinuria in the United States (U.S. commercial launch, partnered distribution).

✅ (13 Jan 2025) Cycle Pharmaceuticals acquired Banner Life Sciences, LLC (corporate acquisition by Cycle noted in company news).

✅ (27 Mar 2025) Advicenne reported 2024 sales and confirmed ADV7103 is in late-stage development for cystinuria in Europe and that interaction with FDA has progressed on the cystinuria development plan.

✅ (30 Jun 2025) Advicenne confirmed plans to finalize regulatory filings and development paths for ADV7103 in cystinuria and stated intentions to pursue US/Europe regulatory steps and partnerships.

✅ (25 Mar 2024 → referenced in 2025 updates) ADV7103 (Advicenne) holds FDA orphan-drug designation in cystinuria (milestone frequently cited in Advicenne 2025 communications about their cystinuria program).

✅ (30 Jun 2025) Kidney Research UK grant awarded for academic research into new cystinuria drug targets (Professor Richard Coward research funding to develop drugs targeting cystine transport pathways).

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/cystinuria-treatment-market?sg

Major Key Players: Travere Therapeutics, Inc., Dr. Reddy's Laboratories Ltd., Advicenne, Teva Pharmaceutical Industries Ltd., ANI Pharmaceuticals, Inc., Viatris Inc., AdvaCare Pharma, Camber Pharmaceuticals, Inc., Bausch Health Companies Inc and Panacea Biotec.

Market Growth Drivers:

✅ Improved diagnosis and genetic testing

Wider availability of genetic tests and greater clinician awareness lead to more confirmed diagnoses. Earlier and accurate diagnosis expands the treatable patient pool and enables personalized management plans.

✅ Advances in pharmacotherapy and pipeline innovation

Research into safer, more effective cystine-binding or cystine-reducing agents and repurposing of existing drugs can shift treatment patterns. Any novel, better-tolerated medical therapy would significantly increase market uptake.

✅ Better surgical and stone-management technologies

Improvements in minimally invasive procedures (ureteroscopy, percutaneous nephrolithotomy, laser lithotripsy) reduce morbidity and hospital stay, increasing the overall spend per managed patient and enabling broader treatment strategies.

✅ Orphan drug incentives and regulatory support

Orphan-designation incentives, accelerated approval pathways, and extended market exclusivity encourage investment into rare-disease treatments, which fuels R&D and commercial interest.

✅ Rising patient and clinician awareness

Education programs, patient advocacy, and specialist networks help earlier referral, diagnosis, and adherence to long-term preventative regimens (hydration, alkalinization, chelation).

✅ Improved reimbursement frameworks

Expanded coverage of rare-disease therapies and inclusion of genetic testing into public or private insurance schemes reduce out-of-pocket burden and increase treatment uptake.

✅ Clinical trial activity and real-world evidence (RWE)

Active clinical programs and publication of RWE demonstrating long-term benefit or cost-effectiveness improve payer confidence and drive adoption.

✅ Telemedicine and remote management tools

Digital health tools that support hydration tracking, urine pH monitoring, and remote follow-up can improve adherence and reduce acute episode costs - making long-term management more viable.

Segments Covered in the Cystinuria Treatment Market:

By Type(Cystinuria Type 1, Cystinuria Type 2, Cystinuria Type 3)

By Drugs(Tiopronin (Thiola), Penicillamine, Captopril, Others)

By Route of Administration(Oral, Injectables)

By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for Cystinuria Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=cystinuria-treatment-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Cystinuria Treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Cystinuria Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Cystinuria Treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Cystinuria Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Cystinuria Treatment market?

➠ Who are the global key manufacturers of the Cystinuria Treatment Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Cystinuria Treatment market opportunities and threats faced by the vendors in the global Cystinuria Treatment Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Cystinuria Treatment market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.